Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
5
Neutral
6
Bullish
3
Bearish
16
Neutral
6
Bullish
24
Bearish
11
Neutral
0
Bullish
21
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Sanjivani Paranteral Limited is a WHO‑GMP certified Indian pharmaceutical manufacturer focused on sterile injectables and oral solid dosage forms, exporting to over 25 countries and operating manufacturing facilities in Navi Mumbai, Dehradun, Pune (SPL Infusion) and Prague (Alevia JV) while serving hospital and distributor channels in emerging markets.
Q3 FY26 performance was robust: standalone revenue of INR208.6 million (up 20.3% YoY), EBITDA of INR38.8 million (up 35.7% YoY) and PAT of INR26.2 million (up 37.8% YoY), with exports contributing roughly 77% of revenue and consolidated numbers showing slightly stronger YoY growth driven by new subsidiaries.
Margins tell a mixed story: gross margin compressed materially year‑on‑year due to higher COGS while EBITDA margin expanded to 18.4% driven by favourable product mix and lower other expenses, indicating the company can protect operating profitability through mix and cost control despite input cost pressure.
The company is transitioning to a multi‑vertical platform — Pune infusion facility has started contributing commercially and Prague nutraceutical JV has begun commercial batches — and management is guiding a material revenue step‑up in FY27, supported by product portfolio expansion and strategic partnerships.
Pharmaceuticals & Biotechnology
Pharmaceuticals
183 Cr
Moderate Risk
27.3
36.7
-1.4
3.8
268.80
126.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
Sanjivani Paranteral Ltd (SANJIVIN) is currently trading at 149.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sanjivani Paranteral Limited is a WHO‑GMP certified Indian pharmaceutical manufacturer focused on sterile injectables and oral solid dosage forms, exporting to over 25 countries and operating manufacturing facilities in Navi Mumbai, Dehradun, Pune (SPL Infusion) and Prague (Alevia JV) while serving hospital and distributor channels in emerging markets. Q3 FY26 performance was robust: standalone revenue of INR208.6 million (up 20.3% YoY), EBITDA of INR38.8 million (up 35.7% YoY) and PAT of INR26.2 million (up 37.8% YoY), with exports contributing roughly 77% of revenue and consolidated numbers showing slightly stronger YoY growth driven by new subsidiaries. Margins tell a mixed story: gross margin compressed materially year‑on‑year due to higher COGS while EBITDA margin expanded to 18.4% driven by favourable product mix and lower other expenses, indicating the company can protect operating profitability through mix and cost control despite input cost pressure. The company is transitioning to a multi‑vertical platform — Pune infusion facility has started contributing commercially and Prague nutraceutical JV has begun commercial batches — and management is guiding a material revenue step‑up in FY27, supported by product portfolio expansion and strategic partnerships.
Over the past 52 weeks, Sanjivani Paranteral Ltd has traded between a low of ₹126.00 and a high of ₹268.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sanjivani Paranteral Ltd has a market capitalization of approximately 182.61. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sanjivani Paranteral Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 27.28 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 182.61 Cr, Sanjivani Paranteral Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sanjivani Paranteral Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sanjivani Paranteral Ltd is 27.28. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
273.75 | 198 Cr | — | 6.46 | 0.00 | 14.29 | 16.99 | 12.01 | ||
64.99 | 189 Cr | 7.69 | 1.54 | 0.00 | 20.04 | 19.30 | 16.59 | ||
51.35 | 188 Cr | — | 0.00 | 0.00 | 41.16 | -26.02 | -14.69 | ||
149.00 | 183 Cr | 27.28 | 3.79 | 0.00 | 13.87 | 16.29 | 7.62 | ||
164.20 | 183 Cr | 18.87 | 3.34 | 0.00 | 17.67 | 20.78 | 12.61 | ||
138.70 | 174 Cr | — | 2.82 | 0.00 | 66.48 | 47.70 | 0.00 | ||
7.14 | 171 Cr | 714.00 | 4.87 | 0.00 | 0.90 | 1.13 | 0.76 | ||
| Median: 7 Co. | — | 138.70 | 183 Cr | 23.08 | 3.34 | 0.00 | 17.67 | 16.99 | 7.62 |
AGM/EGM Notice
Sanjivani Paranteral: Postal ballot notice dated 23-07-2026 seeking approval to issue up to 5,00,000 convertible warrants to promoter Mr. Ashwani Khemka and to approve material RPT with SPL Infusion; e‑voting 24-Jul-2026 to 22-Aug-2026.
Preferential Allotment/QIP
Board approved issue of up to 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka at INR147.39 each (aggregate INR7,36,95,000), convertible within 18 months, subject to shareholders' approval; RPT and postal ballot notice approved.
Preferential Allotment/QIP
Board approved issue of up to 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka at INR 147.39 each (aggregate INR 7,36,95,000), convertible within 18 months, subject to shareholder approval; postal ballot to be held.
Preferential Allotment/QIP
Sanjivani Paranteral Ltd board approved issue of up to 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka at INR 147.39 each (aggregate up to INR 7,36,95,000), subject to shareholders' approval; RPTs and postal ballot notified.
Preferential Allotment/QIP
Board approved issue of up to 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka at INR147.39 each (aggregate ~INR7.37 Cr), convertible within 18 months, subject to shareholders' approval; Postal Ballot and RPT noted.
Board Meeting
Sanjivani Paranteral Ltd: Board meeting on 2026-07-23 to consider raising funds via issuance of warrants/convertible securities (preferential/rights or other modes) and other matters; trading window closed till 48 hrs after Q1 FY2027 results.
